Hassana Fathallah
Overview
Explore the profile of Hassana Fathallah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karim N, Ullah A, Pathrose P, Fathallah H, Perry A, Morris J, et al.
Curr Oncol
. 2022 Jul;
29(7):4779-4790.
PMID: 35877239
Background: Several studies suggest that patients with KRAS-mutant NSCLC fail to benefit from standard systemic therapies and do not respond to EGFR inhibitors. Most recently, KRAS 12c data suggest specific...
2.
Ramlogan-Steel C, Steel J, Fathallah H, Iancu-Rubin C, Atweh G
Blood Cells Mol Dis
. 2020 Dec;
87:102522.
PMID: 33260083
Stathmin 1 (STMN1) is a cytosolic phosphoprotein that was discovered as a result of its high level of expression in leukemic cells. It plays an important role in the regulation...
3.
Wise-Draper T, Moorthy G, Salkeni M, Karim N, Thomas H, Mercer C, et al.
Target Oncol
. 2017 Mar;
12(3):323-332.
PMID: 28357727
Background: The combination of everolimus and the imidazoquinoline derivative, BEZ235 (dactolisib), a dual PI3K/mTOR inhibitor, demonstrated synergy in a preclinical model. Objective: To establish clinical feasibility, a phase Ib dose-escalation...
4.
Atweh G, Fathallah H
Hematol Oncol Clin North Am
. 2010 Nov;
24(6):1131-44.
PMID: 21075284
Reactivation of fetal hemoglobin (HbF) expression is an important therapeutic option in adult patients with hemoglobin disorders. The understanding of the developmental regulation of γ-globin gene expression was followed by...
5.
Fathallah H, Taher A, Bazarbachi A, Atweh G
Blood Cells Mol Dis
. 2009 Apr;
43(1):58-62.
PMID: 19346141
Inducers of fetal hemoglobin (HbF) have shown considerable promise in the treatment of sickle cell disease (SCD). However, the same agents have shown less clinical activity in beta-thalassemia (beta-Thal). To...
6.
DNA hypomethylation therapies and hemoglobin disorders. [An interview with Hassana Fathallah by H&O]
Fathallah H
Clin Adv Hematol Oncol
. 2009 Feb;
6(11):806-8.
PMID: 19194363
No abstract available.
7.
Fathallah H, Portnoy G, Atweh G
Blood Cells Mol Dis
. 2007 Nov;
40(2):166-73.
PMID: 18029204
K562 erythroleukemia cells have been widely used as a model for the study of globin gene regulation. A number of agents have been shown to activate or suppress globin gene...
8.
Fathallah H, Weinberg R, Galperin Y, Sutton M, Atweh G
Blood
. 2007 Jul;
110(9):3391-7.
PMID: 17638855
Butyrate is a prototype of histone deacetylase inhibitors that is believed to reactivate silent genes by inducing epigenetic modifications. Although butyrate was shown to induce fetal hemoglobin (HbF) production in...
9.
Fathallah H, Atweh G
Hematology Am Soc Hematol Educ Program
. 2006 Nov;
:58-62.
PMID: 17124041
Reactivation of fetal hemoglobin (HbF) expression is an important therapeutic option in patients with hemoglobin disorders. In sickle cell disease (SCD), an increase in HbF inhibits the polymerization of sickle...
10.
DNA hypomethylation therapy for hemoglobin disorders: molecular mechanisms and clinical applications
Fathallah H, Atweh G
Blood Rev
. 2006 Mar;
20(4):227-34.
PMID: 16513230
Reactivation of fetal hemoglobin (HbF) expression is an important therapeutic option in patients with hemoglobin disorders. In sickle cell disease (SCD), an increase in HbF would interfere with the polymerization...